An ultra-sensitive and cost-effective diagnostic to improve AML patient outcome.

Reference number
Coordinator Uppsala universitet - Institutionen för immunologi, genetik och patologi
Funding from Vinnova SEK 2 200 000
Project duration July 2019 - June 2021
Status Ongoing
Venture Swelife and Medtech4Health - Collaborative Projects for Improved Health
Call Swelife and Medtech4Health - Collaborative Projects for Improved Health (Spring 2019)

Purpose and goal

Highly sensitive and accurate assays are needed to monitor patients with acute myeloid leukemia (AML), receiving targeted therapies. Early signs of resistance to the therapy can be met with alternate drugs. We will demonstrate that the ultrasensitive sRCA technique, earlier than competing techniques, can sense the presence of mutations heralding therapy resistance, providing a more beneficial treatment outcome. The technology can be generalized to most other malignancies.

Expected results and effects

The project will validate the sRCA technique for detection of therapy-resistant mutations for AML patients at improved sensitivity compared to competing techniques. We will also demonstrate the suitability of the sRCA technique in a clinical setting in term of assay flexibility, robustness, handling time, work load, etc.

Planned approach and implementation

In the University lab we will design and establish sRCA assays for therapy-resistant mutations in AML, and validate the assays as well as the entire work-flow using standard samples. Once the assays reach the desired performance and robustness they will be transferred to the clinical genetics lab at Uppsala University Hospital to analyze patient samples, benchmarking the technique against competing approaches in term of performance and work flow. We will evaluate the business opportunities of this new technology.

The project description has been provided by the project members themselves and the text has not been looked at by our editors.

Last updated 15 May 2019

Reference number 2019-01464

Page statistics